Theravance Biopharma US Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Theravance Biopharma US's estimated annual revenue is currently $37.7M per year.(i)
  • Theravance Biopharma US's estimated revenue per employee is $155,000

Employee Data

  • Theravance Biopharma US has 243 Employees.(i)
  • Theravance Biopharma US grew their employee count by -7% last year.

Theravance Biopharma US's People

NameTitleEmail/Phone
1
Chief Staff, DevelopmentReveal Email/Phone
2
VPReveal Email/Phone
3
CEOReveal Email/Phone
4
SVPReveal Email/Phone
5
Head Quality EuropeReveal Email/Phone
6
VP Head Facilities OperationsReveal Email/Phone
7
Head Investor RelationsReveal Email/Phone
8
VP, BiometricsReveal Email/Phone
9
SVP, General Counsel and Corporate SecretaryReveal Email/Phone
10
VP, CHROReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Theravance Biopharma US?

Theravance Biopharma is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our pipeline of internally discovered programs is targeted to address significant patient needs. Our research is focused in the areas of inflammation and immunology. We have one approved product, YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

keywords:N/A

N/A

Total Funding

243

Number of Employees

$37.7M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Theravance Biopharma US News

2022-04-20 - Staphylococcal Infection Drugs Market Size, Scope And ...

New Jersey, United States – The Staphylococcal Infection Drugs Market report ... The Medicines Company, Theravance Biopharma, Allergan Plc,...

2022-03-30 - Theravance Biopharma, Inc. Announces Results from Study ...

DUBLIN, April 4, 2022 /PRNewswire/ -- Theravance Biopharma, ... orthostatic hypotension (nOH) with patent protection until 2037 in the US.

2022-03-30 - Theravance Biopharma to Participate in an Upcoming Investor ...

DUBLIN, April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: ... of the Theravance Biopharma group of companies (in the US and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$48.6M251-4%$65M
#2
$147.3M261-2%$192.5M
#3
$95.1M2625%N/A
#4
$197.9M266-11%$194.5M
#5
$29.7M2707%N/A